An interventional study of CAREN therapy and Conventional interventions in Neurodevelopmental Disorders, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Neurodevelopmental Disorders with a site in Italy — 18 open to participants now, 24 under way, 6 of them phase 3. Neurodevelopmental Disorders · Italy.
Among the 35 studies in Neurodevelopmental Disorders with a site in Italy, this one is the 8th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, reaches primary completion later than 21 of the 23 other live ones, and was the 29th registered.
355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.
Browse Neurodevelopmental Disorders studies →18 of the 35 studies in Neurodevelopmental Disorders with a site in Italy are open now. Recruiting first, the newest first:
GRIN Therapeutics, Inc. · Sites in Italy, United States, Australia and 10 more countries
Ages 1 mo–18 yrs
Meyer Children's Hospital IRCCS · Sites in Italy, France, Poland
Ages 2–30
Istituto Giannina Gaslini · Sites in Italy
Ages 28 days+
IRCCS Eugenio Medea · Sites in Italy
Ages 2+
Istituto Giannina Gaslini · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 86 across 218 interventional studies indexed under Neurodevelopmental Disorders.
Median enrollment 80 across the 25 interventional studies, 139 across the 10 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 35 have an industry lead sponsor. The 10 most frequent:
IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.
IRCCS Centro Neurolesi Bonino Pulejo has 1 study filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurodevelopmental Disorders with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT06851377IRCCS Eugenio MedeaExpanding NGS Data with Optical Genome Mapping (OGM) | 2026-12 |
| NCT07884227Istituto Giannina GasliniMulti-Omics Genetic Investigation Strategies to Enhance the Diagnostic Workflow for Rare Diseases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 35 studies in Neurodevelopmental Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neurodevelopmental disorders, such as Cerebral Palsy (CP), Attention-Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), are complex conditions that affect various aspects of children's development. Despite advancements in treatments, conventional rehabilitative interventions tend to focus on specific aspects, often overlooking the holistic needs of the patient. Many of these interventions fail to engage children, who may feel uninvolved or demotivated. Innovative technologies, such as immersive virtual reality (IVR), offer a promising alternative to make rehabilitation more engaging and comprehensive. This study aims to evaluate the effects of IVR-based rehabilitation on children and adolescents with neurodevelopmental disorders, focusing on improvements in cognitive, motor, and social functions. We hypothesize that IVR will enhance social interaction, attention, motor skills, and overall quality of life. The study will include children and adolescents aged 8 to 18 years, diagnosed with ADHD, ASD, and cerebral palsy. The CAR-EN platform, which provides a highly customizable therapeutic environment, will be used. Assessments will measure cognitive, motor, and social skills before and after the intervention. We expect immersive virtual reality to lead to significant improvements in the participants' cognitive, motor, and social abilities. These findings could potentially contribute to a shift in therapeutic guidelines, offering more effective treatments for children with neurodevelopmental disorders.
This protocol was created to evaluate the effects of rehabilitation with IVR in subjects with neurodevelopmental disorders that profoundly impact their quality of life and that of their families: Cerebral Palsy (CP), Attention-Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD).
In the literature we find many studies and guidelines concerning the neuropsychological interventions envisaged for the pathologies that affect our protocol.
However, rehabilitation interventions in the developmental age often focus on a single clinical aspect, aiming to implement some deficient skills and losing sight of the global vision of the patient and his needs.
Furthermore, conventional rehabilitation methods do not always appear motivating for the minor, who is often forced to perform the tasks required in a non-participatory and active way.
In recent decades, scientific research has instead highlighted the effectiveness of therapeutic interventions with innovative technologies, demonstrating how these tools can make the rehabilitation process more engaging and stimulating, both for adults and minors.
In particular, the use of Immersive Virtual Reality (IVR) is configured as a promising frontier in neuropsychological rehabilitation, with the potential to significantly improve patients' quality of life and optimize clinical outcomes compared to traditional methods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of one of the following neurodevelopmental disorders:
Exclusion Criteria:
Diagnosis of conditions not related to the target neurodevelopmental disorders, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The treatment group consists of n. 36 children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), n. 36 with Autism Spectrum Disorder (ASD) and n. 36 with Cerebral Palsy (CP). The intervention was tailored to individual needs and aimed at evaluating the efficacy of motor and cognitive treatment in an immersive virtual reality environment, in support of conventional therapy.
Behavioral: CAREN therapy · Behavioral: Conventional interventions
Arm Description: The treatment group consists of n. 36 children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), n. 36 with Autism Spectrum Disorder (ASD) and n. 36 with Cerebral Palsy (CP). The intervention was tailored to individual needs and aimed at evaluating the efficacy of motor and cognitive treatment in conventional therapy.
Behavioral: Conventional interventions
The experimental intervention uses the CAREN immersive virtual reality system, which integrates visual, auditory and tactile sensory stimuli, to stimulate cognitive, motor and social skills through interactive exercises. The system monitors progress in real time and reduces the stress associated with traditional therapies, offering an innovative and engaging therapy experience.
\- Neuropsychomotricity for children with cerebral palsy, with the objectives of motor improvement, balance and coordination. - Cognitive-behavioral training for ADHD, focusing on attentional skills, planning and emotional self-regulation. - Cognitive-behavioral training for ASD, focusing on cognitive flexibility, impulse control and motor coordination.
Visual Attention and Memory Assessed by the Leiter International Performance Scale - Third Edition (Leiter-3)
The primary outcome will be assessed using the Attention and Memory subtests of the Leiter International Performance Scale - Third Edition (Leiter-3), a standardized nonverbal cognitive assessment tool commonly used in children and adolescents. These subtests evaluate sustained attention, selective attention, visual working memory, immediate memory recall, and delayed memory recall. Higher raw and standardized scores indicate better cognitive performance in the assessed domains.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Gross Motor Function Assessed by the Gross Motor Function Measure-66 (GMFM-66)
Gross motor function will be assessed using the Gross Motor Function Measure-66 (GMFM-66), a standardized observational assessment tool designed to evaluate changes in gross motor abilities in children with motor disabilities. The GMFM-66 provides an interval-level total score derived from 66 items covering key domains of gross motor function, including lying and rolling, sitting, crawling and kneeling, standing, walking, running, and jumping. Higher scores indicate better gross motor function.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Muscle Spasticity Assessed by the Modified Ashworth Scale (MAS)
Muscle spasticity will be assessed using the Modified Ashworth Scale (MAS), a standardized clinical rating scale used to measure resistance to passive soft-tissue stretching as an indicator of muscle spasticity. The MAS is scored on a 5-point ordinal scale ranging from 0 to 4, where 0 indicates no increase in muscle tone and 4 indicates affected parts rigid in flexion or extension. Higher scores indicate greater muscle spasticity, reflecting a worse outcome.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Balance Assessed by the Tinetti Assessment Tool - Balance Subscale
Balance will be assessed using the Balance Subscale of the Tinetti Assessment Tool, a standardized clinical scale designed to evaluate postural stability as part of functional mobility and fall risk assessment. The Balance Subscale is scored on a range from 0 to 16, with higher scores indicating better balance and a lower risk of falls. Lower scores indicate reduced mobility and higher fall risk.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Attention and Memory Assessed by the NEPSY-Second Edition (NEPSY-II)
The outcome will be assessed using the Attention and Memory domain of the NEPSY-Second Edition (NEPSY-II), a standardized developmental neuropsychological assessment battery designed to evaluate cognitive functioning in children. The Attention and Memory domain includes subtests assessing sustained attention, selective attention, auditory and visual attention, immediate and delayed memory, and working memory. Scores are reported as age-normed scaled scores derived from standardized test performance. Higher scores indicate better attention and memory functioning.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Executive Function Assessed by the Tower of London Test
Executive functioning will be assessed using the Tower of London Test, a standardized neuropsychological assessment designed to evaluate executive functions, particularly planning ability, problem-solving, and working memory. Outcome parameters include the total number of correct solutions, number of moves, and task completion time. Higher performance scores indicate better executive functioning, whereas a greater number of errors or longer completion times indicate poorer performance.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Executive Function Assessed by the Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2)
Executive functioning will be assessed using the Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2), a standardized caregiver-report questionnaire designed to evaluate everyday executive function behaviors in children and adolescents aged 5 to 18 years. The BRIEF-2 yields three index scores-Behavior Regulation Index, Emotion Regulation Index, and Cognitive Regulation Index-as well as a Global Executive Composite (GEC) score, derived from nine clinical scales. All outcomes are reported as age-normed T-scores. Higher T-scores indicate greater executive function difficulties, reflecting worse outcomes.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Behavioral and Attention Symptoms Assessed by the Conners' Rating Scales - Third Edition (Conners 3)
Behavioral, emotional, and attention-related symptoms will be assessed using the Conners' Rating Scales - Third Edition (Conners 3), a standardized caregiver- and teacher-report questionnaire designed to evaluate behavioral and attentional difficulties in children and adolescents. The Conners 3 provides T-scores across multiple clinical scales, including Inattention, Hyperactivity/Impulsivity, Executive Functioning, Learning Problems, Aggression, and Peer Relations, based on age- and sex-normed data. Higher T-scores indicate greater severity of behavioral and attention-related symptoms, reflecting worse outcomes.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Behavioral and Emotional Problems Assessed by the Child Behavior Checklist (CBCL) - Parent Version
This outcome will be assessed using the Child Behavior Checklist (CBCL), a standardized caregiver-report questionnaire designed to evaluate emotional and behavioral problems in children and adolescents. The CBCL provides syndrome scale scores (e.g., Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Rule-Breaking Behavior, Aggressive Behavior) and broad-band composite scores (Internalizing, Externalizing, and Total Problems). Scores are reported as T-scores, derived from age- and gender-normed data. Higher T-scores indicate greater behavioral or emotional difficulties, representing a worse outcome.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), 3-month follow-up (T3)
Motor Competence Assessed by the Movement Assessment Battery for Children - Second Edition (Movement ABC-2)
Motor competence in children and adolescents will be assessed using the Movement Assessment Battery for Children - Second Edition (Movement ABC-2), a standardized test. The Movement ABC-2 evaluates three motor domains: Manual Dexterity, Aiming and Catching, and Balance (static and dynamic). The assessment provides age-standardized scores, a Total Motor Score, and percentile rankings. Higher scores indicate better motor performance, whereas lower scores reflect greater motor coordination difficulties, representing a worse outcome.
Time frame: T0 (Baseline), T1 (1 month), T2 (3 months), T3 (Follow-up at 3 months)
System Usability Assessed by the System Usability Scale (SUS)
System usability will be assessed using the System Usability Scale (SUS), a standardized 10-item questionnaire designed to measure users' perceived usability of a system or device. The SUS provides a total score ranging from 0 to 100, calculated according to the standard scoring method. Higher scores indicate better perceived usability, with scores above 68 generally considered above average usability.
Time frame: Up to 7 months
Behavioral Safety Assessed by the Behavioral Safety Event Rating Scale (B-SERS)
Behavioral safety will be assessed using the Behavioral Safety Event Rating Scale (B-SERS), based on a behavioral risk assessment framework. The B-SERS evaluates the frequency and severity of safety-related behavioral events, such as behaviors that may pose a risk to oneself, others, or the environment. The scale includes 5 items, each scored from 0 to 4 (0 = no event; 1 = mild; 2 = moderate; 3 = marked; 4 = severe). The total score ranges from 0 to 20, with higher scores indicating worse safety outcomes.
Time frame: Up to 7 months
Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 29 months after the start.
Of 142 non-industry interventional studies with no phase under Neurodevelopmental Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 29 months is close to that.
Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →
IRCCS Centro Neurolesi Bonino Pulejo